Management of Alcohol Withdrawal Syndrome

Introduction

Alcohol withdrawal syndrome is a serious condition that requires prompt medical attention, with treatment guidelines supported by the American Association for the Study of Liver Diseases and the American Academy of Family Physicians 1, 2, 3

Benzodiazepines are the "gold standard" for treating alcohol withdrawal syndrome, being more effective than clometiazol, with robust evidence supporting their use, as recommended by the American Association for the Study of Liver Diseases 1, 2
In patients with liver dysfunction, short- or intermediate-acting benzodiazepines such as lorazepam or oxazepam are preferred 2, 4, 5
A symptom-triggered approach, where medication is given based on CIWA-Ar scores, is a recommended treatment strategy, with the following score categorization:
Score Withdrawal Severity
<8 Mild
8-14 Moderate
≥15 Severe [1, 2, 5, 4]
Benzodiazepines, such as diazepam (initial dose of 10 mg IV for acute agitation, tremor, or impending delirium tremens, and maintenance doses of 5-10 mg IV every 3-4 hours as needed) or lorazepam (1-4 mg PO/IV/IM every 4-8 hours), are the standard pharmacological treatment for alcohol withdrawal syndrome, with lorazepam preferred for patients with hepatic dysfunction 4, 5

Acamprosate is a safer alternative for patients with liver disease to prevent relapse after complete detoxification 2, 6
Baclofen is a promising medication for patients with alcoholic liver disease to prevent relapse after complete detoxification 2
Naltrexone and disulfiram may also be considered for preventing relapse, although disulfiram should be avoided in patients with severe alcoholic liver disease due to its potential hepatotoxicity 6, 2

Disulfiram should be avoided in patients with severe alcoholic liver disease due to its potential hepatotoxicity 2
Clometiazol is used in Europe, but it lacks robust evidence and shares the potential risk of abuse with benzodiazepines, and should not be used beyond the initial 10-14 days of treatment 1
Increased risk of falls, especially in elderly patients, is a concern when using medication for alcohol withdrawal, as stated by the American Academy of Family Physicians 3
Regular use of medication for alcohol withdrawal can lead to tolerance and dependence, with paradoxical agitation occurring in approximately 10% of patients 7, 3

Thiamine supplementation (100-300 mg/day IV or PO) is essential to prevent Wernicke encephalopathy, with strong evidence support, and should be continued for 2-3 months after resolution of withdrawal symptoms, as recommended by the American Association for the Study of Liver Diseases 1, 5, 4
Electrolyte replacement, particularly magnesium, potassium, and phosphate, and hydration with adequate fluid intake are essential adjunctive treatments, as recommended by the National Institute on Alcohol Abuse and Alcoholism 1, 5
Fiber supplementation is recommended to improve stool consistency in patients with fecal incontinence during alcohol withdrawal, and elimination of dietary triggers such as caffeine, sorbitol, and fructose is advised to manage fecal incontinence, as suggested by the American Gastroenterological Association 8
Loperamide (2 mg) may be used as a first-line treatment for fecal incontinence, starting with 1 tablet 30 minutes before breakfast and titrating as necessary up to 16 mg daily, as recommended by the American Gastroenterological Association 8

Phosphatidylethanol (PEth) in blood detects alcohol use for 10-14 days with high specificity, and Ethyl glucuronide (EtG) in urine detects alcohol use for up to 80 hours with 89% sensitivity and 99% specificity, according to the American Association for the Study of Liver Diseases 1
Ethyl sulfate (EtS) is complementary to EtG testing, as stated by the American Association for the Study of Liver Diseases 9
PEth in blood or EtG in urine are preferred over indirect markers like GGT or CDT for monitoring abstinence, according to the American Association for the Study of Liver Diseases 1
For long-term monitoring, consider hair EtG (hEtG) which can detect alcohol use for up to 6 months, as recommended by the American Association for the Study of Liver Diseases 1

Psychiatric consultation is recommended for evaluation, treatment planning, and long-term abstinence planning, and comprehensive psychosocial support, including individual psychotherapy, psychoeducation, group therapy, and cognitive behavioral therapy, is an important component of long-term management, as recommended by the American College of Physicians and the Clinical and Molecular Hepatology guidelines 5
After successful withdrawal management, consider medications to prevent relapse, such as acamprosate, naltrexone, and disulfiram, and refer patients to specialized addiction services and mutual help groups, such as Alcoholics Anonymous, as recommended by clinical guidelines 6, 5
Complete and permanent cessation of alcohol consumption is recommended for patients with alcohol-related liver disease, as stated by the American Association for the Study of Liver Diseases 10